Update shared on15 Aug 2025
With both Net Profit Margin and Consensus Revenue Growth forecasts holding steady, analyst expectations for Nano-X Imaging remain unchanged, maintaining the price target at $7.75.
What's in the News
- Nano-X Imaging announced a clinical and educational collaboration with Keiser University to deploy the Nanox.ARC imaging system at the Sarasota campus for training and demonstrations.
- The partnership aims to educate healthcare professionals and increase usage of Nanox.ARC's clinical protocols, offering on-campus access to students, physicians, radiology technicians, and local providers.
- Nanox.ARC’s proprietary 3D imaging technology improves sensitivity and specificity over traditional X-ray, reduces patient radiation exposure, and shortens radiology reading times compared to CT.
Valuation Changes
Summary of Valuation Changes for Nano-X Imaging
- The Consensus Analyst Price Target remained effectively unchanged, at $7.75.
- The Net Profit Margin for Nano-X Imaging remained effectively unchanged, at 5.38%.
- The Consensus Revenue Growth forecasts for Nano-X Imaging remained effectively unchanged, at 82.8% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.